The net sales revenues in the first half of 2023 were RON162.2 million, up 17% compared to RON138.6 million on June 30, 2022. Expenses grew almost 20% to RON107.6 million and overall, assets grew 5.4% to RON400.6 million.

“In the first semester of 2023, Biofarm S.A. took the 2nd place in the Consumer Healthcare (CHC) segment, in terms of the number of sold units. Biofarm portfolio covers the most important therapeutic areas in the Consumer Healthcare division (digestive & metabolic, respiratory & ENT, cardiovascular & circulatory, nervous system, multivitamins), and is the volume market leader in the reference categories of 6 of its brands: Colebil, Triferment, Bixtonim Solution, Carmol, Extravalerian and Sennalax. In terms of value, Biofarm consolidated its sales to the final consumer, recording a 24% increase as compared to the first semester of 2022, in relation to the purchase price in pharmacies”, company representatives said in the report.

BIO shares have gained 14.3% so far in 2023, amid deals worth RON2.6 million, ensuring a market value of almost RON700 million. The company is 52%-owned by SIF Muntenia (SIF4.RO) and 10.2% by Lion Capital (LION, the former SIF Banat-Crisana).

“Considering the long-term direction, Biofarm S.A. attaches great importance to its new product development centre, which will play a vital role in implementing plans for the coming years. The continuous development of new and revolutionary products is one of the key growth pillars of Biofarm S.A., which will strengthen the company’s leading position in the pharmaceutical industry”, the report also reads.

For 2023, Biofarm envisages a turnover of RON325 million, up 17% on the year, and a profit of almost RON75 million, up 6% from 2022. With the result of the first half of 2023, the company achieved roughly two thirds of the profit anticipated for the whole 2023.